1. Home
  2. AMSF vs CGEM Comparison

AMSF vs CGEM Comparison

Compare AMSF & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMERISAFE Inc.

AMSF

AMERISAFE Inc.

HOLD

Current Price

$38.57

Market Cap

730.9M

Sector

Finance

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$10.21

Market Cap

671.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMSF
CGEM
Founded
1985
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Accident &Health Insurance
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
730.9M
671.7M
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
AMSF
CGEM
Price
$38.57
$10.21
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$58.33
$28.00
AVG Volume (30 Days)
182.9K
1.2M
Earning Date
10-29-2025
11-06-2025
Dividend Yield
6.63%
N/A
EPS Growth
N/A
N/A
EPS
2.60
N/A
Revenue
$309,746,000.00
N/A
Revenue This Year
$4.26
N/A
Revenue Next Year
$4.48
N/A
P/E Ratio
$14.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$36.34
$5.68
52 Week High
$53.27
$13.33

Technical Indicators

Market Signals
Indicator
AMSF
CGEM
Relative Strength Index (RSI) 42.77 49.52
Support Level $37.85 $9.48
Resistance Level $39.64 $10.38
Average True Range (ATR) 0.81 0.89
MACD 0.03 -0.24
Stochastic Oscillator 63.29 19.61

Price Performance

Historical Comparison
AMSF
CGEM

About AMSF AMERISAFE Inc.

AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: